The use of human papillomavirus seroepidemiology to inform vaccine policy
- PMID: 19773679
- PMCID: PMC4237610
- DOI: 10.1097/OLQ.0b013e3181bce102
The use of human papillomavirus seroepidemiology to inform vaccine policy
Comment on
-
HPV 6/11, 16, 18 seroprevalence in men in two US cities.Sex Transm Dis. 2009 Nov;36(11):671-4. doi: 10.1097/OLQ.0b013e3181bc094b. Sex Transm Dis. 2009. PMID: 19809385
Similar articles
-
Vaccine policy analyses can benefit from natural history studies of human papillomavirus in men.J Infect Dis. 2007 Oct 15;196(8):1117-9. doi: 10.1086/521199. Epub 2007 Sep 13. J Infect Dis. 2007. PMID: 17955427 No abstract available.
-
No Vacillation on HPV Vaccination.Cell. 2018 Mar 8;172(6):1163-1167. doi: 10.1016/j.cell.2018.02.045. Cell. 2018. PMID: 29522737
-
[Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].Salud Publica Mex. 2009 Jul-Aug;51(4):336-41. doi: 10.1590/s0036-36342009000400011. Salud Publica Mex. 2009. PMID: 19668929 Spanish. No abstract available.
-
Towards global prevention of human papillomavirus-induced cancer.Eur J Immunol. 2008 Feb;38(2):323-6. doi: 10.1002/eji.200890002. Eur J Immunol. 2008. PMID: 18228245 Review. No abstract available.
-
Implications for human papillomavirus in penile cancer.Urol Oncol. 2014 Jan;32(1):53.e1-8. doi: 10.1016/j.urolonc.2013.08.010. Epub 2013 Nov 13. Urol Oncol. 2014. PMID: 24239463 Review.
Cited by
-
Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.Int J Cancer. 2013 Nov;133(9):2172-81. doi: 10.1002/ijc.28215. Epub 2013 May 29. Int J Cancer. 2013. PMID: 23588935 Free PMC article. Clinical Trial.
-
Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.J Natl Cancer Inst. 2010 Dec 1;102(23):1794-804. doi: 10.1093/jnci/djq436. Epub 2010 Nov 23. J Natl Cancer Inst. 2010. PMID: 21098758 Free PMC article.
-
Human papillomavirus testing in the prevention of cervical cancer.J Natl Cancer Inst. 2011 Mar 2;103(5):368-83. doi: 10.1093/jnci/djq562. Epub 2011 Jan 31. J Natl Cancer Inst. 2011. PMID: 21282563 Free PMC article. Review.
-
The known unknowns of HPV natural history.J Clin Invest. 2011 Dec;121(12):4593-9. doi: 10.1172/JCI57149. Epub 2011 Dec 1. J Clin Invest. 2011. PMID: 22133884 Free PMC article. Review.
-
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women.Tumour Virus Res. 2022 Jun;13:200236. doi: 10.1016/j.tvr.2022.200236. Epub 2022 May 4. Tumour Virus Res. 2022. PMID: 35525430 Free PMC article. Clinical Trial.
References
-
- Dunne EF, Nielson CM, Hagensee ME, Papenfuss MR, Harris RB, Herrel N, et al. HPV 6/11, 16, 18 seroprevalence in men in two U.S. cities. Sex Transm Dis. 20092009 Ref Type: Journal (Full) - PubMed
-
- Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):324–7. - PubMed
-
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007 Sep 8;370(9590):890–907. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical